Patient Guide: Belzutifan (MK-6482) in combination with Fulvestrant for ER+/HER2- unresectable/metastatic breast cancer (MK-6482-029/LITESPARK-029)

We'll Help You Connect with This Trial

Quri.ai is a free clinical trial matching service. We help patients like you connect directly with research sites conducting this study.

  • Get matched to the right study location for you
  • Connect directly with study coordinators at multiple participating sites
  • Understand eligibility with our simplified screening tool
  • Free service - we're here to help you access clinical research
Trial ID: NCTMK-6482-029
Status: 🟢 Enrolling Now
Condition: ER-positive breast cancer, HER2-negative breast cancer, metastatic breast cancer
Phase: NA

Loading interactive enrollment tools...

The full interactive experience will load momentarily